Adenovirus formulations
CA 2799545 A1 · Owner: Merck Sharp & Dohme Corp. · Inventors: Evans, Robert K.; Volkin, David B.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to viral formulations and related pharmaceutical products for use in , gene therapy and/or vaccine applications. Especially preferred viral formulations disclosed , herein are liquid adenovirus formulations which show improved stability when , stored in about the 2-8°C range while also being compatible with parenteral administration. These , formulations comprise a buffer a sugar, a salt, a divalent cation, a nonionic detergent, as , well as a free radical cavenger and/or a chelating agent to inhibit free radical oxidation.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 6, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 6, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 6, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.